Developmental aspects of the renal responses to hemorrhage during converting-enzyme inhibition in fetal lambs.
The role of the renin-angiotensin system in modulating the renal hemodynamic and functional responses to reductions of fetoplacental blood volume (8.8-35.5%) was studied in two groups of fetal lambs (less than 120 days and greater than 130 days gestation; term 145 days) during infusion of either captopril (experimental fetuses) or dextrose 5% in water (control fetuses). At high hemorrhage levels (level III), renal blood flow decreased and renal vascular resistance increased significantly in both groups of fetuses (less than 120 days and greater than 130 days), either treated or not treated with captopril. However, at low hemorrhage levels (levels I and II), and contrary to what was observed in young fetuses (less than 120 days), near-term fetuses (greater than 130 days) receiving captopril showed neither significant decreases in renal blood flow nor increases in renal vascular resistance, whereas untreated fetuses of the same gestational ages demonstrated significant decreases in renal blood flow and increases in renal vascular resistance. It was found in both less than 120 day and greater than 130 day fetuses that hemorrhage is associated with a decrease in urinary flow rate and free water clearance accompanied by an increase in urine osmolality and sodium reabsorption. It was shown that captopril does not modify this response. The present study also demonstrated that the blood pressure response to hemorrhage was characterized by a similar decrease in less than 120 day fetuses, whether treated or untreated with captopril. On the other hand, blood pressure did not change in control fetuses greater than 130 days, but decreased slightly in captopril-treated fetuses during hemorrhage. Taken together, the present results tend to suggest that the renin-angiotensin system may be an important modulator of the renal hemodynamic response to low level hemorrhage as fetuses approach term, and may be more important in controlling blood pressure in near-term than in young fetuses.
D000450:Aldosterone / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001784:Blood Gas Analysis; D002216:Captopril / Q000008:administration & dosage; D002395:Catecholamines / Q000097:blood; D005260:Female; D005333:Fetus / Q000502:physiology*; D006439:Hemodynamics; D006470:Hemorrhage / Q000503:physiopathology*; D007668:Kidney / Q000503:physiopathology; D007703:Peptidyl-Dipeptidase A / Q000097:blood / Q000502:physiology; D011188:Potassium / Q000097:blood; D011247:Pregnancy; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects; D012756:Sheep
D000806:Angiotensin-Converting Enzyme Inhibitors; D002395:Catecholamines; D000450:Aldosterone; D002216:Captopril; D007703:Peptidyl-Dipeptidase A; D012083:Renin; D011188:Potassium